% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{DeSantis:298945,
      author       = {A. De Santis$^*$ and L. Zhu$^*$ and J. Tao$^*$ and C.
                      Reißfelder and S. Schölch$^*$},
      title        = {{M}olecular subtypes of intrahepatic cholangiocarcinoma.},
      journal      = {Trends in molecular medicine},
      volume       = {31},
      number       = {8},
      issn         = {1471-4914},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier Science},
      reportid     = {DKFZ-2025-00379},
      pages        = {755-769},
      year         = {2025},
      note         = {#EA:A430#LA:A430# / 2025 Aug;31(8):755-769},
      abstract     = {Intrahepatic cholangiocarcinoma (iCCA) presents in two
                      clinically distinct subtypes: large duct (LD-iCCA) and small
                      duct (SD-iCCA). These subtypes exhibit significant
                      molecular, genetic, and histopathological differences that
                      impact patient prognosis and treatment responsiveness. This
                      review advocates for a subtype-specific approach to iCCA
                      research and clinical management, including tailored
                      therapeutic strategies that consider distinct genetic
                      profiles and tumor microenvironments. Current therapeutic
                      approaches hold promise, yet efficacy varies by subtype.
                      Additionally, subtype-specific molecular diagnostics,
                      including DNA methylation-based classifiers and
                      transcriptomic sequencing, have shown potential in refining
                      iCCA subclassification, thereby guiding precision medicine
                      efforts. This article outlines existing clinical trials, key
                      research trajectories, and future directions for developing
                      more effective subtype-adapted therapies for iCCA.},
      subtyp        = {Review Article},
      keywords     = {clinical trial (Other) / intrahepatic cholangiocarcinoma
                      (Other) / molecular targeted therapy (Other) / mutation
                      (Other) / survival (Other) / translational research (Other)},
      cin          = {A430},
      ddc          = {610},
      cid          = {I:(DE-He78)A430-20160331},
      pnm          = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
      pid          = {G:(DE-HGF)POF4-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39955217},
      doi          = {10.1016/j.molmed.2025.01.008},
      url          = {https://inrepo02.dkfz.de/record/298945},
}